Rachel Morris
Grifols Therapeutics Internship
During the Summer of 2025, I participated in a Bioanalytics Biology Internship at Grifols Therapeutics. While I cannot disclose much about this experience, I was able to participate in the evaluation of the mechanism of action for a new immunoglobulin therapy. Click the button below to view the slides summarizing my internship for the MMB program.
What Did I Do?
My main project revolves around a new immunoglobulin drug that Grifols is manufacturing, originally developed by the German company Biotest, which was acquired by Grifols in 2022. My project involved evaluating the MOA of this drug through the use of ELISAs and other assays. I gained significant experience in a GxP space and was able to network with many individuals in high-ranking roles within the company. The interns also had the opportunity to tour facilities with each stage of the plasma therapeutics development process, starting with the plasma donation centers, all the way to the manufacturing center in Clayton.